Novartis AG subsidiaries are defendants in 108 cases brought by about 112 plaintiffs claiming to have been injured by hormone replacement therapy products.
Discovery is underway in these cases, according to the Company’s annual report, on Form 20-F, filed with the…
Novartis AG subsidiaries face about 570 cases brought in United States courts in which plaintiffs claim to have experienced osteonecrosis of the jaw after having been treated with Zometa or Aredia.
All purported class actions have been dismissed. Discovery is continuing…
Various pharmaceutical companies, including Novartis AG subsidiaries, face cases that allege the fraudulent overstatement of Average Wholesale Price and “best price.”
The AWP and “best price” are, or have been, used by the U.S. federal and state governments in the calculation…
Novartis AG says that settlement discussions covering both civil and criminal investigations, over the potential off-label promotion of Trileptal, are ongoing.
Trileptal is the Company’s epilepsy drug.
The U.S. Attorney’s Office for the Eastern District of Pennsylvania served an administrative subpoena under…